Business
Medovex Corporation’s DenerveX System Demonstrates Clinical Benefits in Patients Suffering from Low Back Facet Joint Pain
Medovex Corporation’s DenerveX System Demonstrates Clinical Benefits in Patients Suffering from Low Back Facet Joint Pain.
About this update from Innoveren Scientific Inc.
[{"type":"text","content":"\nReview of Real World Cases from Five Independent Sites Across Europe Demonstrated Reduction in Pain Scores and General Improvement of Health Metrics up to 6 Months Following Treatment as Evidenced by VASBACK, ODI and EQ-5D-5L.\n ATLANTA, July 02, 2018 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB:MDVX) (\"Medovex\" or the \"Company\"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced the release of patient data that demonstrates clinical benefits of its DenerveX System in patients suffering from low back facet joint pain at 6 months post-treatment. Facet Joint Syndrome (FJS) is among the leading causes of low back pain and affects millions globally. Typically manifesting from spinal osteoarthritis (OA), FJS is a painful, chronic condition whose treatment options, often temporary in nature, have remained unchanged in the past four decades. Medovex’s DenerveX is a novel, minimally invasive system developed to provide potential long-term relief via a combination of controlled thermal energy and rotational capsular tissue shaving of the bony structure to disrupt nociceptive signals and receptors. The Company hypothesized that use of this novel system would result in sustained pain relief and improved health metrics associated with mobility.  Methods This prospective multicenter European cohort included patients with chronic intractable pain of the low back resulting from FJS who had failed conservative treatments for pain. Patients who were treated between July 2017 and February 2018 were evaluated for joint groupings treated, pain and quality of life as measured by the visual analog score (VAS), medication log, Oswestry Disability Index (ODI) and EQ-5D-5L. Follow-up was conducted at 1, 3, and 6 months post-treatment; data reported correspond to these time points. Results Results from 61 patients (60.7% females; average age 55.1±11.5 years) were evaluated. Prior to treatment, 47 patients regularly used one or more prescribed analgesics and had predominately undergone either physiotherapy (81.4%), spinal injections (86.4%), or both to help alleviate pain. A total of seven joint groupings were ...